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Abstract
Channelopathies, caused by disturbed potassium or calcium ion management in cardiac myocytes are a major cause of
heart failure and sudden cardiac death worldwide. The human ryanodine receptor 2 (RYR2) is one of the key players tightly
regulating calcium efflux from the sarcoplasmic reticulum to the cytosol and found frequently mutated (,60%) in context
of catecholaminergic polymorphic ventricular tachycardia (CPVT1). We tested 35 Kazakhstani patients with episodes of
ventricular arrhythmia, two of those with classical CPVT characteristics and 33 patients with monomorphic idiopathic
ventricular arrhythmia, for variants in the hot-spot regions of the RYR2 gene. This approach revealed two novel variants; one
de-novo RYR2 mutation (c13892A.T; p.D4631V) in a CPVT patient and a novel rare variant (c5428G.C; p.V1810L) of
uncertain significance in a patient with VT of idiopathic origin which we suggest represents a low-penetrance or
susceptibility variant. In addition we identified a known variant previously associated with arrhythmogenic right ventricular
dysplasia type2 (ARVD2). Combining sets of prediction scores and reference databases appeared fundamental to predict the
pathogenic potential of novel and rare missense variants in populations where genotype data are rare.
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Introduction
Ventricular arrhythmias are the leading cause of morbidity and
mortality worldwide, causing more than 300,000 sudden cardiac
deaths (SCD) each year in the United States and making this a
major public health concern [1]. Approximately 5 to 12% of these
deaths occur in previously asymptomatic seemingly healthy
subjects. In the past few years, the genetic basis of several
monogenetically inherited arrhythmogenic syndromes has been
discovered, providing novel insights to the molecular understand-
ing of diseases predisposing to SCD [2,3]. On the basis of this
knowledge, it has become apparent that ‘‘idiopathic cardiac
arrest’’ may be caused by subclinical or misdiagnosed forms of
arrhythmogenic diseases that eluded clinical diagnosis until they
unexpectedly manifest with SCD [4]. At least some arrhythmias
are caused by one or more mutations in genes that control
electrical conduction through the heart by altering calcium
homeostasis or depolarization or repolarization gradients in the
ventricle. Mutations in these genes can lead to defective cardiac
ion channels, causing ventricular arrhythmias [1–5].
Since its identification as the major candidate gene in
autosomal-dominantly inherited forms of CPVT, more than 180
genetic variants, mostly missense mutations of the RyR2 gene have
been attributed to arrhythmogenic disorders including CPVT1
(OMIM 604772) and ARVD2 (OMIM 600996) [6,7]. CPVT is
characterized by exercise- or stress-induced ventricular arrhyth-
mia, syncope, or early sudden death, but not at rest. Patients with
CPVT have morphologically normal hearts [7–9].
Recent work has elucidated that the vast majority of mutations
mainly cluster to four regions of the RYR-2 channel encoded by
45 exons [10]. While clusters I-III (I: aa44-466, II: 2246-2534, III:
3778-4201) locate to the large N-terminal cytoplasmic region (aa1-
4500) cluster IV (aa4497-4959) locates or to the SR transmem-
brane region [10,11]. The localization of the mutations at the
various N-terminal, central domain or C-terminal of the protein
consistently reported an increased activation of the mutant RYR2
channels to luminal Ca2+ activation [12] with few exceptions.
ARVD2 associated RYR2 mutations (p.R176Q, p.L433P,
p.N2386I and p.T2504M) locate to two distinct clusters in the
cytosolic part of the molecule that correspond to the mutational
domains of the skeletal muscle RYR1 channel causing malignant
hyperthermia (MH) or central core disease (CCD).
A rarer autosomal-recessive form of inherited CPVT (CPVT2;
OMIM 611938) has been associated with homozygous or
compound heterozygous mutations in the gene encoding calse-
questrin-2 CASQ-2. Mutations in the triadin (TRDN; CPVT5),
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calmodulin-1 (CALM1; CPVT4) and the inward rectifying
potassium channel gene KCNJ2 have also been associated with
autosomal dominant forms of CPVT [13,14]. Another chromo-
somal locus associated with a severe form of CPVT in a
consanguineous family has been mapped to 7p14-p22 (CPVT3)
[15].
CPVT has a high mortality rate of up to 50% by the age of 30
years, but since b-blockers and/or implantable cardioverter-
defibrillator (ICD) can at least partially prevent arrhythmias and
sudden death, early diagnosis through clinical and genetic
screening is essential for effective clinical management of patient’s
suffering from RYR-2 mediated arrhythmia [16]. The introduc-
tion of ‘‘high-speed’’ sequencing technologies in modern pathology
has highlighted the unprecedented potential to rapidly detect
novel genetic variants but at the same time unrevealed the high
risk for misclassification in case of rare genetic variants in the past
[17]. Despite of the easily accessible and continuously growing
number of high-quality exome and genome sequencing databases
and improved user-friendly in-silico prediction tools, considerable
caution has to be taken to separate genetic noise from truly disease
causing rare variants especially in populations where genetic data
are rare. In a first pilot study we screened 35 unrelated patients
from our Kazakhstani ventricular tachycardia study cohort
suffering from ventricular tachycardia (most of them idiopathic)
for genetic variants in the mutational hot-spot regions of the
RYR2 gene and classified the observed variants. The demographic
background of our patient study group is 54.3% (19/35) Kazakh,
34.3% (12/35) Russian, and 11.4% others (Table S1 in File S1).
Material and Methods
Study participants
The study was performed under the appropriate institutional
ethics approvals and in accordance with the principles embodied
in the Declaration of Helsinki. A study protocol was approved by
the Ethics Committee of the Nazarbayev University. Informed
written consent was obtained from all participants. Participants
provided written informed consent to include case details in the
paper. A clinical diagnosis of ventricular tachycardia was verified
in all patients by the authors (M.B., O.N.) and other physicians of
the National Scientific Cardiac Surgery Center (NSCC). Of these
patients, 2 were classified as ‘‘CPVT phenotype’’ because of
exertional syncope plus documentation of bidirectional or
polymorphic ventricular tachycardia (Case #271, Case #239),
and 33 were classified as idiopathic ventricular tachycardia (Case
#444 and others). The subjects and their relatives were
investigated at the NSCC. They underwent basic clinical
investigation, and history was focused on possible CPVT
symptoms, that is, syncope during exercise, history of sudden
cardiac death in the family (Overview patient information is given
in Table S1 in File S1.
DNA sequencing of RYR2 mutational hot-spot exons
Genomic DNA was isolated from EDTA blood samples using
QIAGEN blood DNA Mini Kit (QIAGEN, Hilden, Germany).
Since previous studies consistently detected disease-associated
variants within three distinct hot-spot regions of the RYR2 gene,
which encode critical functional and regulatory domains of the
channel, we focused sequence analysis to these 45 exons (3, 8, 10,
12–15, 17, 19, 21, 26–28, 37, 40–50, 75, 83, 86–93, 95–97, 99–
105) [10,18].
We used 20 ng of DNA per PCR in a total volume of 20 ml
using Hot Start Plus Polymerase (QIAGEN, Hilden, Germany)
and a four primer reaction set-up. The primer-set included 1 ml of
10 pmol M13 forward tagged gene-specific forward, and M13
reverse tagged gene-specific reverse primers each and 0.2 ml of
10 pmol gene-specific forward and reverse primers each (both
overlapping to 100% with their M13-tagged counterparts regard-
ing the gene-specific sequence). Primers were re-designed based on
published primer sequences [18] and updated according to the
latest db entry for the hRYR2 gene (ENSG00000198626; from
ENSEMBL data base release GRCh37; date of primer design:
Oct. 23rd, 2012). Primer sequences are listed in Table S2 in File
S1. For all amplicons the same standard PCR cycling conditions
were used: 96uC for 5 min followed by 8 cycles of 95uC for 45 sec,
57uC for 30 sec and 72uC for 45 sec, 27 cycles of 95uC for 30 sec,
68uC for 30 sec and 72uC for 45 sec and a final extension step of
72uC for 10 min. PCR products were purified using the
Marchery&Nagel PCR clean-up system in an automated setting
with a Hamilton Starlet liquid handling robot. Sequencing
reactions were run using 3.1. BigDye Terminator chemistry and
M13 forward or M13 reverse sequencing primers according to
standard cycling conditions, purified and sequenced on an ABI
3730 DNA Sequencer (Life Technologies). Sequence analysis was
done both, electronically (DNAStar, Lasergene, SeqMan Tool)
with the SNP discovery threshold set to 35% and manually. As
reference sequence of the human RYR2 gene, GenBank entry
NM_001035 was used.
Classification of genetic variants
To predict the possible impact of amino acid substitutions, the
following prediction tools were used: 1) SIFT (Sorting Intolerant
From Tolerant, v.4.05) [19], 2) PolyPhen-2 (Polymorphism
Phenotyping v2) [20], 3) Grantham Score [21], 4) MutationTa-
ster2 [22], and 5) Conservation. In addition, the databases of the
1000Genomes and the Exome Sequencing Project (ESP;
n = 6,503) and the Human Genome Mutation Database were
queried to further evaluate and/or validate the variants in a
second dimension. Additionally, samples of 192 Kazakh individ-
uals (KazCG) and samples of 96 unrelated breast cancer patients
from the Kazakh population were used as a control group (Kazakh
Breast Cancer Study Cohort (KazBCSC). We classified our
missense variants related to a recently proposed classification
system [23]. For conservative classification we defined a missense
variant as possibly damaging variant when at least three of the five
prediction tools predicted the variant damaging and when
ESP6500, the 1000Genomes or the Kazakh Control Group
(KazCG; n= 192) databases were negative for the variant. With
three or less than three ‘‘damaging’’ predictions but at least one
positive entry in one of the three databases a variant was called
Variant of Unknown Significance (VUS).
Results
Case #271
We observed missense variant p.V1810L (c5428G.C; Fig.1 a)
in a 42 year old male Korean. The initial diagnosis was idiopathic
arrhythmia characterized by unstable paroxysms of ventricular
tachycardia. The age of VT onset was 41 with negative anamnesis
for cases SCD or heart failure in his family. He was admitted to
the NSCC with complaints of monotone pains and left hand
numbness unrelated physical stress. ECG Holter monitoring fixed
episodes of unstable ventricular tachycardia. ECHO-CG did not
reveal any structural heart pathologies. Thread mill test was
negative and tolerance towards physical stress high. A detailed
summary of clinical characteristics and ECG data is shown in
Table S1 in File S1 and Figure S1 in File S1.
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Resting ECG. The ECG heart rhythm at rest was sinusoid
with 49 beats/min, a normal QRS axis, a normal PR interval
(188 ms), QRS (74) ms and QT (446 ms), QTC (402 ms). There
were no ST-T or T wave abnormalities.
VT characteristics. At the time of VT onset, the preceding
sinus rate at VT onset was 83 beats/min, bigeminy. The VT heart
rate was 220 beats/min, CL - 227 ms. VT complexes (n = 14) at
onset were non sustained with a duration of paroxysms of 3.2 sec.
The VT was monomorphic. Wide QRS-complex tachycardia with
elements for diagnosis of VT (AV dissociation), probably
originating in the left ventricle were observed. CL is changing
depicting warming-up phenomenon (non-reentrant mechanism).
RYR2 variant prediction. The genetic variant c5428G.C
encoding p.V1810L was identified in patient #271 (Table 1).
Three out of five algorithms predicted this variant damaging. In
addition, the ESP6500, the 1000Genomes Project and the KazCG
were negative for the variant whereas one female patient of the
KazBCSC carried the same genetic variant. Unfortunately, the
control subject was not available for further clinical examination.
The family history of the index patient was negative for cases of
sudden cardiac death or cardiac rhythm disturbances. The index
patient’s asymptomatic mother was tested negative for the variant;
the father did not participate in the study.
Case #239
Missense variant p.D4631V RYR2 (c13892A.T, Fig. 1 b) was
detected in a 23 year old female Kazakh. Age of symptom onset
was 13 years with recurrent episodes of syncope and occurrence of
characteristic ECG patterns with mono/polymorphic ventricular
premature beats followed by bi-directional ventricular tachycardia
and salvos of polymorphic ventricular tachycardia.
She was initially admitted to NSCC with complaints about
paroxysms of heart palpitation, breathlessness at exercise, weak-
ness and fatigue. She suffered palpitation, dizziness, seizures,
episodes of syncope, frequent respiratory infections, chronic
pyelonephritis and scoliosis since childhood. At age of 16 CPVT
was diagnosed followed by radiofrequency ablation of the right
ventricle and the cava tricuspid isthmus due to the high risk of
SCD. In the same year a cardioverter defibrillator was implanted
and beta blockers administered. During the follow up period and
during ICD programming she perceived episodes of presyncope
due to ventricular tachycardia of 260 ms cycle length. Ventricular
tachycardia was treated by burst stimulation. Family history was
negative for episodes of syncope and SCD. A detailed summary of
clinical characteristics and ECG data is shown in Table S1in File
S1 and Figure S2 in File S1.
Resting ECG. The ECG heart rhythm at rest was sinusoid
with 60 beats/min, a normal QRS axis, a normal PR interval
(166 ms), QRS (96) ms and QT (432 ms), QTC (428 ms). There
were no ST-T or T wave abnormalities. The arrhythmias detected
at rest were premature ventricular beats and atrial tachycardia.
Figure 1. Electropherograms of RYR2 sequences from patients
#271 (a), #239 (b), and #444 (c).
doi:10.1371/journal.pone.0101059.g001
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VT characteristics. At the time of VT onset, QRS complex
was relatively narrow, at 90 ms. The preceding sinus rate at
CPVT onset was 119 beats/min, bigeminy. The CPVT heart rate
was 234 beats/min, CL- 260 ms. The recurrent CPVT was
polymorphic and bidirectional.
The QRS morphology is characteristic of bidirectional ventric-
ular tachycardia changed every 5–6 beats, typically with inferior
and superior axis or right bundle branch block and left bundle
branch block patterns. CPVT was induced by exercise. Exercise
test was not performed.
Catecholamine infusion test was not performed.
Pathogenicity Predication. RYR2 missense variant
p.D4631V was predicted pathologic/disease causing by five out
of five prediction algorithms (Table 1). The variant was neither
reported in the ESP6500, the 1000 Genomes database nor found
in the KazCG or the KazBCSC. There was no indication of SCD,
heart failure or less severe cardiac disorders in the family history.
In the absence of strong co-segregation – both parents were tested
negative for the variants - or functional studies the p.D4631V de-
novo variant must still be considered as possibly pathogenic.
Case #444
The variant p.T2504M (c7511C.T) was detected in 20 year
old female Kazakh. She was diagnosed with cardiac arrhythmia,
unstable ventricular tachycardia. The age of onset of VT was 19
years. She was under outpatient observation of cardiologist for the
reason of premature ventricular beats, and was admitted to the
NSCC with complaints of shortness of breath at slight physical
activity, general weakness, periodic pains and irregular heartbeats.
No structural abnormalities were detected by ECHO-CG. The
patient was treated with anti-arrhythmic drugs, but they were not
effective for premature ventricular contractions and ventricular
tachycardia. Thus the radiofrequency ablation of arrhythmogenic
focus located in the right ventricular outflow tract was performed
twice, the last one was successful and following 24-hour ECG
monitoring showed no arrhythmia manifestation. A detailed
summary of clinical characteristics and ECG data is shown in
Table S1 in File S1 and Figure S3 in File S1.
Resting ECG. The ECG heart rhythm at rest was sinusoid
with 76 beats/min. The electrical heart axis was at vertical
position. PR (140) ms, QRS (86) ms, QT (382 ms), QTC (398 ms).
The ST-T waves were normal.
VT characteristics. 24-hour ECG Holter monitoring re-
vealed 6642 ventricular episodes with morphology of LBBB, where
PVBs 600, bigeminy PVBs 332, paired PVBs 1544, paroxysms of
VT 192 with maximum of 5 complexes.
The observed missense variant RYR2 p.T2504M (c7511C.T,
Fig. 1 c) has been reported in context of ARVD2 (HGMD
CM010424) previously [6]. ARVD2 phenotypes mimic and
overlap with CPVT phenotypes since structural abnormalities
(myocyte loss with fatty or fibro-fatty tissue replacement predom-
inantly of the right ventricle) frequently lack or remain undetected
using non-invasive imaging methods. In-silico prediction strongly
suggests a disease causing consequence of the mutation (Table 1).
Discussion
RYR2 mutations have been attributed to a spectrum of variable
and converging clinical phenotypes such as patients with
reproducible bidirectional VT and polymorphic VT at exercise
stress testing; patients presenting only with polymorphic VT; and
patients with idiopathic VT. Even more, the occurrence of
CPVT1 and ARVD2 even within the same family raised the
suggestion that the two entities might correspond to different
degrees of phenotypic expression of the same disease [13].
Considering the various phenotypes and the variable penetrance
of the numerous RYR2 mutations, we thought to investigate 35
patients, 33 of them diagnosed with idiopathic VT for mutations in
the RYR2 gene in a pilot study. We observed a heterozygous
missense mutation at c13892A.T (p.D4631V; Case #239) with
high pathogenic potential (high in-silico prediction scores, de-
novo, reference databases negative) in a patient with classical
clinical characteristics of CPVT. The penetrance of this de-novo
variant has to be considered high due to the early age of onset and
the distinctive and severe clinical course. Due to ongoing
symptoms and risk of SCD index patient #239 is considered to
undergo the selective sympathectomy. The ARVD2 variant
p.T2504M has been observed in a 20-year old patient with
idiopathic ventricular tachycardia. Index patient #444 had a
successful RFA and anti-arrhythmic drugs need not be prescribed.
However, based on the identification of the ARVD2 associated
RYR2 gene mutation, the patient management strategy was
modified. MRI of the heart is planned to perform to detect any
arrhythmogenic dysplasia.
The third variants (p.V1810L; Case #271) pathogenic impact
on RYR2 channel function remains elusive. Late disease onset and
lack of other clinical CPVT characteristics argue against a
mechanistic association with the phenotype. However, considering
the severity of CPVT misdiagnosis, we may have to consider such
rare genetic variants as low-penetrance or susceptibility variants
predisposing carriers to CPVT-like symptoms under certain
conditions unless a neutral effect is proven; if only in functional
studies. The variant detected in index patient #271 was found in
an asymptomatic offspring of the patient. Clinical evaluation of the
offspring did not indicate any structural heart abnormalities. The
baseline ECG was unremarkable. On the basis of genetic testing,
the boy was recommended to remain under regular observation by
cardiologists. We ascertained allele frequencies of the RYR2
variants in a collective of 288 unrelated individuals of Kazakh
background (96 Breast cancer patients, 192 healthy control
individuals) and only identified variant p.V1810L in an unrelated
female breast cancer patient (Table 2). Seven common RYR2
Table 2. Frequency of RYR2 single nucleotide variants.
Variant KazVTSG ESP6500 1000 Genomes 96 KazBCSC 192 KazCG HGMD
T2504M 0.0286 Neg. Neg. Neg. Neg. CM010424
V1810L 0.0286 Neg. Neg. 0.0104 Neg. Neg.
D4631V 0.0286 Neg. Neg. Neg. Neg. Neg.
KazVTSG: Kazakh Ventricular Tachycardia Study Group (n = 35). KazBCSC: Kazakh Breast Cancer Study Cohort (n = 96). KazCG: Kazakh control group (n = 192). HGMD:
Human Genome Mutation Database. ESP6500, the 1000Genomes and the 192 KazCG are negative for the observed RYR2 variants. Variant p.V1810L was detected in 1/96
unrelated female breast cancer patient from the KazBCSC.
doi:10.1371/journal.pone.0101059.t002
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single nucleotide polymorphisms with varying allele frequencies in
ethnic groups (Table 3) were tested among the VT study group
and yielded comparable frequencies. Intermediate allele frequen-
cies for individual SNPs are a result of the heterogeneous
demographic background of the VT study group.
To date, no genotype-based risk stratification or differential
treatment approach has been suggested based on CPVT-positive
variants. However, early genetic testing is recommended by the
Heart Rhythm Society and the European Heart Rhythm
Association for clinical management and therapeutic decisions
involving family members, because CPVT may present as SCD or
Sudden Infant Death Syndrome as the first manifestation
[13,14,18]. It is a life-saving challenge to ascertain whether and
how the effect of low-penetrance variants is modeled by the
genetic background or non-genetic factors (life-style, environmen-
tal stressors, etc.). Especially a close clinical follow-up of low-
penetrance variant carriers will essentially contribute to the
understanding of further risk factors and their impact on disease
onset and progression.
Supporting Information
File S1 Supporting Tables and Figures. This file contains
Table S1, Table S2, and Figure S1- Figure S3. Table S1, Patient
data and medical history. Table S2, RYR2 oligonucleotide
sequences. Figure S1, Electrocardiogram of Case #271. Figure
S2, Electrocardiogram of Case #239. Figure S3, Electrocardio-
gram of Case #444.
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